Phar­ma­to­ry set to expand Oulu’s phar­ma­ceu­ti­cal man­u­fac­tur­ing capa­bil­i­ties in 2028

At a time when much of the dis­cus­sion around Euro­pean man­u­fac­tur­ing focus­es on indus­tri­al decline and the chal­lenges of main­tain­ing pro­duc­tion capac­i­ty, one Oulu-based man­u­fac­tur­er, Phar­ma­to­ry, is tak­ing a sig­nif­i­cant step for­ward. 

Found­ed in 2001, Phar­ma­to­ry devel­ops man­u­fac­tur­ing process­es and pro­duces active phar­ma­ceu­ti­cal ingre­di­ents (APIs) — the chem­i­cal sub­stances that form the basis of med­i­cines. Work­ing with phar­ma­ceu­ti­cal and biotech­nol­o­gy com­pa­nies around the world, the com­pa­ny has built its exper­tise on solv­ing com­plex chem­istry chal­lenges and turn­ing lab­o­ra­to­ry process­es into reli­able man­u­fac­tur­ing oper­a­tions. Now, Phar­ma­to­ry is prepar­ing for its next chap­ter, with a new facil­i­ty ded­i­cat­ed to high­ly potent active phar­ma­ceu­ti­cal ingre­di­ents (HPA­PIs) sched­uled to begin oper­a­tions in 2028. 

The expan­sion is being sup­port­ed by invest­ment from Finnish pri­vate equi­ty investor MB Funds, help­ing to accel­er­ate the devel­op­ment of new man­u­fac­tur­ing infra­struc­ture and Phar­ma­to­ry’s entry into the grow­ing HPA­PI mar­ket. 

A dif­fer­ent lev­el of con­tain­ment 

HPA­PIs are used in med­i­cines such as can­cer treat­ments and oth­er tar­get­ed ther­a­pies. While the chem­istry involved may be famil­iar to expe­ri­enced phar­ma­ceu­ti­cal man­u­fac­tur­ers, work­ing with these com­pounds brings an entire­ly dif­fer­ent set of chal­lenges. Because they can have bio­log­i­cal effects at extreme­ly low con­cen­tra­tions, their man­u­fac­ture requires spe­cialised facil­i­ties, equip­ment and work­ing prac­tices. Con­tain­ment sys­tems are essen­tial to pro­tect employ­ees from expo­sure and pre­vent cross-con­t­a­m­i­na­tion between prod­ucts. 

“Man­u­fac­tur­ing high­ly potent com­pounds requires us to look at the entire process, from mate­r­i­al han­dling and syn­the­sis to clean­ing and waste man­age­ment. It’s not sim­ply a ques­tion of pro­duc­ing the com­pound itself, but mak­ing sure every stage can be car­ried out safe­ly and reli­ably,” says Phar­ma­to­ry’s Man­ag­ing Direc­tor, Dr Jaana Kar­jalainen. 

Prepar­ing for pro­duc­tion 

As prepa­ra­tions con­tin­ue for the open­ing of its new facil­i­ty, Phar­ma­to­ry recent­ly wel­comed con­tain­ment spe­cial­ists from SafeBridge Europe and con­tain­ment tech­nol­o­gy com­pa­ny ILC Dover to its Oulu site. 

Togeth­er, the teams test­ed new­ly installed pro­duc­tion iso­la­tors. These enclosed sys­tems are designed to pre­vent expo­sure to high­ly potent phar­ma­ceu­ti­cal ingre­di­ents. More than 180 sam­ples were col­lect­ed to ver­i­fy the equip­men­t’s con­tain­ment per­for­mance and ensure it meets safe­ty require­ments ahead of pro­duc­tion. 

As the project reached its final test­ing phase, the vis­it­ing team reflect­ed pos­i­tive­ly on the col­lab­o­ra­tion: 

“Simon Adcock & Neil Cock­er of ILC Dover (an Inger­soll Rand Com­pa­ny) recent­ly vis­it­ed Phar­ma­to­ry to com­plete the final stages of a High Con­tain­ment project — test­ing the three recent­ly installed Flex­i­ble Con­tain­ment Iso­la­tors specif­i­cal­ly designed to upgrade the exist­ing equip­ment and process­es. Hav­ing start­ed the project with an ini­tial site vis­it in Novem­ber 2024, Simon & Neil have devel­oped a close work­ing rela­tion­ship with the Phar­ma­to­ry Team, exceed­ing the tra­di­tion­al customer/supplier rela­tion­ship to one bor­der­ing on friend­ship, a key fac­tor to the suc­cess of the project. While the pri­ma­ry focus has always been deliv­ery of the Con­tain­ment sys­tems, each vis­it to Oulu has been mem­o­rable for the kind hos­pi­tal­i­ty shown by our hosts & the wel­com­ing locals with incred­i­ble local cuisine—sampling rein­deer cooked many dif­fer­ent ways has been a def­i­nite high­light! We are very much look­ing for­ward to the next stage of devel­op­ment at Phar­ma­to­ry and to return vis­its, hope­ful­ly in the warmer sum­mer months!” 

A new mile­stone for Phar­ma­to­ry 

“For Phar­ma­to­ry, this invest­ment rep­re­sents an impor­tant step in our future growth. It will allow us to sup­port cus­tomers whose drug can­di­dates require spe­cialised man­u­fac­tur­ing capa­bil­i­ties, while build­ing on the chem­istry exper­tise we have devel­oped over the past 25 years.” says Dr. Jaana Kar­jalainen. “We are proud to be tak­ing this next step in Oulu, strength­en­ing local phar­ma­ceu­ti­cal exper­tise and con­tribut­ing to the region’s life sci­ence ecosys­tem.” 

The new facil­i­ty will broad­en Phar­ma­to­ry’s capa­bil­i­ties and cre­ate oppor­tu­ni­ties to work on a wider range of phar­ma­ceu­ti­cal projects. It also marks anoth­er step for­ward for Oulu’s grow­ing life sci­ence sec­tor. With oper­a­tions sched­uled to begin in 2028, Phar­ma­to­ry is look­ing ahead to sup­port­ing the devel­op­ment of tomor­row’s med­i­cines from its home in Laani­la, Oulu.

Source (text and image): Phar­ma­to­ry